STOCK TITAN
  1. Home
  2. News
  3. ICVX

Icosavax, Inc. - $ICVX STOCK NEWS

Welcome to our dedicated page for Icosavax news (Ticker: $ICVX), a resource for investors and traders seeking the latest updates and insights on Icosavax stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Icosavax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Icosavax's position in the market.

News
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Rhea-AI Summary
AstraZeneca (NASDAQ: ICVX) has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will strengthen AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12, targeting both RSV and hMPV, two leading causes of severe respiratory infection and hospitalization in adults 60 years of age and older and those with chronic conditions. The upfront cash portion of the consideration represents a transaction value of approximately $0.8bn, a 43% premium to Icosavax’s closing market price on 11th December 2023. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $1.1bn, a 91% premium to Icosavax’s closing market price on 11th December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
acquisition clinical trial
-
News
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Rhea-AI Summary
Icosavax, Inc. (Nasdaq: ICVX) has entered into a definitive agreement with AstraZeneca for a tender offer to acquire all outstanding shares for $15.00 per share in cash at closing, with a non-tradable contingent value right of up to $5.00 per share, representing a total equity value of up to $1.1 billion. The acquisition is expected to close in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.48%
Tags
acquisition
-
News
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Rhea-AI Summary
Icosavax, Inc. (Nasdaq: ICVX) announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. IVX-A12 induced robust immune responses to both viruses and was generally well-tolerated, consistent with prior Phase 1 data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.48%
Tags
clinical trial
News
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Icosavax, Inc. (ICVX) reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV. The company also completed candidate selection for SARS-CoV-2 and influenza programs, highlighting its antigen design capabilities. Cash and cash equivalents, and short-term investments of $229.2 million were reported at the end of 3Q 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.81%
Tags
earnings
-
News
Icosavax to Participate in the Jefferies London Healthcare Conference
Rhea-AI Summary
ICVX: Icosavax to Participate in Jefferies London Healthcare Conference, CEO to Host Fireside Chat on VLP Platform Technology and Pan-Respiratory Vaccines
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
-
News
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Rhea-AI Summary
Icosavax, Inc. will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference. The CEO will participate in a fireside chat and interested parties can access the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
News
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Summary
Icosavax, Inc. to participate in Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
News
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Icosavax, Inc. (Nasdaq: ICVX) reported positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. They also announced a registered direct offering of common stock, closed at $67.8 million, extending cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
earnings
-
News
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
News
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
clinical trial
Stock ICVX logo
Icosavax, Inc.

Nasdaq:ICVX

ICVX Rankings

N/A Ranked by Market Cap
#221 Ranked by Stock Gains
N/A Ranked by Dividends

ICVX Stock Data

769.04M
29.30M
3.47%
87.64%
0.64%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Seattle

About ICVX

icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. the company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the institute for protein design at the university of washington. icosavax is located in seattle.